Status of progess to fix sustainable growth rate physician formula, other rheumatology-related issues facing Congress
Search results for: biosimilars
EULAR 2014: Biosimilar Drug Production Raises Concerns
Rheumatology experts question biosimilars’ safety, efficacy given their complex production process
Rheumatology Advocacy Starts at Home
The ACR expands advocacy efforts to impact state legislatures, local organizations
Rheumatology Drug Updates, Trials, Safety Data
Legislative news on biosimilars, safety warning on epidural corticosteroid injections, and other drug updates rheumatologists need to know
What’s New in Inflammatory Arthritis?
Rheumatology experts at the ACR’s State-of-the-Art Clinical Symposium in Chicago discuss latest drug therapies, insights into axial spondyloarthritis and bone erosion, repair
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
When Will Generic Biologic Drugs Become Commercially Available?
Biosimilars are challenging to produce, but progress is being made
ACR/ARHP Annual Meeting 2012: Federal Act Aims to Make New Biologic Drugs Available to Rheumatology Patients at a Lower Cost
The Biologics Price Competition and Innovation Act of 2009 would spur the development of products intended to be biosimilar to approved therapies
South Korea Okays First Officially Approved Monoclonal Antibody for RA
11 Products Looking for U.S. Marketing Nod
Biosimilar Drugs Face Challenges to Reach the U.S. Market
To date, the FDA has not approved a biosimilar product. In its own discussion of the merits and obstacles to biosimilar drugs, the ACR sponsored a panel session titled, “Biosimilar Products in the U.S. Market: Fact or Fiction?” at the 2011 ACR/ARHP Annual Scientific Meeting here in November.